A study cited by BioPharma Dive says that drug price increases in Germany could lead to higher costs for US patients. The report comes as tensions rise between the US and Germany over pharmaceutical pricing, with several large companies reducing their investments in Germany.
This development may affect global pricing strategies and investment flows for pharma firms. Senior executives should consider the risk of price changes in one market affecting costs and access in others, especially as regulatory pressures and market responses intensify.
